EUVIMEDAvasta EUVIMED
EUVIMED · CrossrefJournal

Annals of Oncology

ISSN 0923-7534 · Elsevier BV

Latest articles

  1. 2RO Retrospective exploratory biomarker (BM) analyses from evERA breast cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) setting

    S.M. Tolaney, J. Liang, W. Darbonne, E. Mayer, M. Martin, G.A. Vidal, L. Moscetti, K. Jhaveri, A.M. Brufsky, W.J. Gradishar, A. Schneeweiss, J.A. O'Shaughnessy, M. Dieterich, L. Lam, T. Fernando, H.S. Rugo

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.011

  2. 3RO 18F-FES PET–defined whole-body ER heterogeneity identifies endocrine responsiveness and predicts survival in ER+/HER2− metastatic breast cancer (MBC): Results of a prospective international clinical trial

    A. Gennari, S. Nardin, E.G.C. Brain, A. Piccardo, A. De Censi, M. Lambertini, F. Matteucci, R. Wuerstlein, R. Seban, F. Fiz, B. Ruffilli, D. Corradengo, G.M. Sacchetti, V. Fontana, O. Nanni, M. Palleschi, V. Rossi, F. D'Avanzo, L. Boni, N. Harbeck

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.012

  3. 13P Sacituzumab govitecan in heavily pretreated and elderly patients with metastatic triple-negative breast cancer: A real-world multicentre study

    M. Kubeczko, A.Z. Konieczna, M. Pieniazek, J. Zubrowska, M. Holanek, R. Soumarova, H. Studentova, M. Malejcikova, K. Winsko-Szczęsnowicz, M. Lisik-Habib, D. Krejci, J. Sustr, I. Kolárová, I. Danielewicz, L. Rusinova, A. Polakiewicz-Gilowska, R. Pacholczak-Madej, M. Jarzab, Z. Bielcikova, M. Puskulluoglu

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.022

  4. 16P Clinical characteristics and outcomes of endocrine-resistant hormone receptor positive, HER2-negative (HR+/HER2−) advanced breast cancer: Insights from the AGO-B CAPTOR trial

    T. Decker, H. Huebner, A.D. Hartkopf, H-C. Kolberg, M.A.M. Thill, J.C. Radosa, B. Lex, N. Ditsch, K. Luedtke-Heckenkamp, M. Van Mackelenbergh, C. Schem, P. Kreis, A. Schneeweiss, W. Janni, T.N. Fehm, V. Mueller, M. Banys- Paluchowski, G. Heinrich, P.A.A. Fasching, M. Schmidt

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.025

  5. 17P Final long-term outcomes of palbociclib-fulvestrant vs. placebo-fulvestrant in HR+/HER2‒ endocrine-sensitive advanced breast cancer: GEICAM/2014-12 (FLIPPER) phase II trial

    J. Albanell, M.T.M. Martinez, L. de la Cruz Merino, M. O'Connor, A.M. Santaballa Bertran, N. Martinez, F. Moreno Anton, I. Fernandez, J.D. Alarcon, J.A. Virizuela Echaburu, J. De la Haba Rodriguez, P. Sanchez-Rovira, L. Gonzalez-Cortijo, I. González Maeso, J.A. Guerra Martínez, M. Ruiz Borrego, C. Bueno Muiño, M. Casas, S. Bezares Montes, F. Rojo

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.026

Volumes

2026 · 6,2202025 · 5,4172024 · 4,0812023 · 4,2972022 · 4,1692021 · 3,5592020 · 3,7712019 · 4,8272018 · 4,1002017 · 4,4342016 · 4,4432015 · 2,8282014 · 3,0172013 · 1,6382012 · 3,6772011 · 6822010 · 7522009 · 5872008 · 7882007 · 6592006 · 6912005 · 6102004 · 4962003 · 4402002 · 5282001 · 6822000 · 6611999 · 7921998 · 5881997 · 5641996 · 5671995 · 4261994 · 5201993 · 4181992 · 4631991 · 3441990 · 197

Teadmised, mis sobivad teie tööga.

Tasuta alustamisest ja isiklikust kirjanduse otsingust kuni täieliku Research Suite’ini.

Vaata pakette →

Kas kõik kirjastajate täistekstid on kaasatud?

Ei. Bibliograafilised kirjed, kokkuvõtted ja täistekstid on erinevad sisud. See, kas täistekst on saadaval, sõltub allikast, Open Accessist ja teie olemasolevatest litsentsidest. EUVIMED-i pakett ei asenda täiendavaid kirjastajaõigusi.